Artivion to Participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference
Artivion (NYSE:AORT) will participate virtually in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference with a fireside chat on March 17, 2026 at 9:20 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Artivion (NYSE:AORT) will participate virtually in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference with a fireside chat on March 17, 2026 at 9:20 a.m. ET.
According to Artivion, the live webcast will be accessible on the company's Investors page and an archived copy will be available for 90 days.
Details
News Market Reaction – AORT
On Mar 4, the first trading day after this news, AORT closed 0.31% below the previous close.
Data tracked by StockTitan Argus for the Mar 4 session.
Key Figures
- Conference fireside chat time
- 9:20 a.m. ET
- Oppenheimer 36th Annual Healthcare MedTech & Services Conference on Mar 17, 2026
- Webcast archive period
- 90 days
- Duration webcast replay will be available on Artivion’s website
- Current share price
- $38.55
- Price before conference participation announcement
- 52-week high
- $48.25
- Upper end of 52-week trading range pre-announcement
- 52-week low
- $21.97
- Lower end of 52-week trading range pre-announcement
- Market capitalization
- $1,841,955,500
- Equity value prior to conference news
- CEO RSU tax sale
- 14,911 shares at $38.0249
- Form 4 sale to cover tax withholding on vested restricted stock units
- Holloway Form 144 proposed sale
- 2,183 shares
- Proposed sale tied to restricted stock vesting on 02/27/2026
Historical Context
-
Strong Q4 and full-year 2025 results with double-digit revenue growth.
-
Favorable IDE trial outcomes for NEXUS TRIOMPHE and AMDS PERSEVERE.
-
Announcement of Q4 2025 results release and teleconference details.
-
Strong Q3 revenue, higher adjusted EBITDA, and raised 2025 guidance.
-
First patient treated in ARTIZEN pivotal trial for Arcevo LSA stent graft.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
form 4 regulatory
form 144 regulatory
restricted stock units financial
sell to cover financial
pma regulatory
ide trial medical
aortic arch medical
webcast technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
A live webcast can be accessed through Artivion's website, www.artivion.com, on the Investors page. An archived copy of the webcast will be available for 90 days on the same website.
About Artivion, Inc.
Headquartered in suburban
Contacts:
Artivion | Gilmartin Group LLC |
Lance A. Berry | Brian Johnston |
Executive Vice President, | Laine Morgan |
Chief Operating Officer & | Phone: 332-895-3222 |
Chief Financial Officer | |
Phone: 770-419-3355 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/artivion-to-participate-in-the-oppenheimer-36th-annual-healthcare-medtech--services-conference-302703016.html
SOURCE Artivion, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.